<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520063</url>
  </required_header>
  <id_info>
    <org_study_id>F150701004 (UAB 1514)</org_study_id>
    <nct_id>NCT02520063</nct_id>
  </id_info>
  <brief_title>Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test how well a new combination of three drugs (Letrozole, Everolimus, and&#xD;
      TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to&#xD;
      definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers&#xD;
      while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational&#xD;
      drug that blocks the formation and growth of blood vessels that feed the cancer and promote&#xD;
      its growth. The goal of this study is to investigate the safety and efficacy of this&#xD;
      multitargeted approach in breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In postmenopausal women with hormone receptor-positive and Her2 negative non-metastatic&#xD;
      breast cancer, downstaging or the achievement of a complete pathologic remission before&#xD;
      definitive surgery has been associated with the lowest risk of recurrence of breast cancer.&#xD;
      In order to achieve a better response in these patients in the preoperative setting, this&#xD;
      study combines 3 potentially synergistic agents. Letrozole blocks the synthesis of estrogens&#xD;
      and, in doing so, deprives the tumor from hormones which drive its growth. Everolimus is a&#xD;
      drug that blocks growth factor signaling which is essential for tumor cells to maintain their&#xD;
      growth and proliferation. Everolimus has already been shown to work very well in this subtype&#xD;
      of breast cancer in the recurrent and metastatic setting. TRC105 is an investigational agent&#xD;
      that prevents the formation and growth of new blood vessels that support tumors by providing&#xD;
      oxygen and nutrients.&#xD;
&#xD;
      The study has 2 components. First the investigators will determine the ideal in terms of&#xD;
      tolerance combination of doses of the 3 agents. Once the ideal regimen is determined, more&#xD;
      patients will be treated with the investigational combination. During this second stage, the&#xD;
      investigators will get a preliminary idea of how effective the investigational therapy is.&#xD;
      Further studies will need to be done to confirm the efficacy of the investigational&#xD;
      combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The highest dose at which 0 out of the first 3 or 1 out of a total of 6 patients experience dose limiting toxicity associated with the combination of letrozole with everolimus and TRC105 during the first cycle of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of pathologic complete remission (pCR)</measure>
    <time_frame>24 weeks up to time of surgery</time_frame>
    <description>The 2-dimensional size of the surgically excised residual tumor will be measure and compared to the radiographic size of the tumor at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max</measure>
    <time_frame>collections over 24 hours on Day 1 and Day 25</time_frame>
    <description>Maximum serum concentration of the interaction between TRC105 and everolimus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor proliferation changes</measure>
    <time_frame>24 weeks up to time of surgery</time_frame>
    <description>Determine the changes in tumor cell proliferation by means of changes in Ki67 expression and changes in serum concentration of markers of angiogenesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>collections over 24 hours on Day 1 and Day 25</time_frame>
    <description>Time of maximum serum concentration of the interaction between TRC105 and everolimus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>collections over 24 hours on Day 1 and Day 25</time_frame>
    <description>Area under the serum concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T 1/2</measure>
    <time_frame>collections over 24 hours on Day 1 and Day 25</time_frame>
    <description>Terminal half-life of the interaction between TRC105 and everolimus</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Cohort -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.</description>
    <arm_group_label>Phase I Cohort -1</arm_group_label>
    <arm_group_label>Phase I Cohort 1</arm_group_label>
    <arm_group_label>Phase I Cohort 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.</description>
    <arm_group_label>Phase I Cohort -1</arm_group_label>
    <arm_group_label>Phase I Cohort 1</arm_group_label>
    <arm_group_label>Phase I Cohort 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <description>The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.</description>
    <arm_group_label>Phase I Cohort -1</arm_group_label>
    <arm_group_label>Phase I Cohort 1</arm_group_label>
    <arm_group_label>Phase I Cohort 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recent diagnosis of hormone receptor positive and HER2 negative breast cancer.&#xD;
&#xD;
          -  Stage 2 and 3 hormone receptor positive and HER2 negative breast cancer (stage T2-4&#xD;
             but not inflammatory, N0-2, M0).&#xD;
&#xD;
          -  Histological grade I, II or III according to the modified Bloom Richardson scale.&#xD;
&#xD;
          -  No prior treatment specific for breast cancer.&#xD;
&#xD;
          -  Postmenopausal status as defined by the National Comprehensive Cancer Network.&#xD;
&#xD;
          -  ECOG performance status &lt; 2 (Karnofsky &gt; 60%).&#xD;
&#xD;
          -  Must have signed study-specific informed consent.&#xD;
&#xD;
          -  Liver Function Tests &lt; 2.5 times the upper normal limit (UNL).&#xD;
&#xD;
          -  ANC ≥ 1,500/mm3, platelets ≥ 100,000/mm3, Hemoglobin ≥ 10g%.&#xD;
&#xD;
          -  Renal function: serum creatinine &lt; 1.5 institutional UNL or creatinine clearance &gt; 40&#xD;
             cc/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory breast cancer.&#xD;
&#xD;
          -  Pre- and peri-menopausal state.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Metastatic disease.&#xD;
&#xD;
          -  HER2 positive breast cancer by immunohistochemistry or FISH.&#xD;
&#xD;
          -  Triple negative breast cancer (hormone receptor and Her2 negative).&#xD;
&#xD;
          -  Disease that cannot be followed by imaging studies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Stringer-Reasor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erica Stringer-Reasor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Erica Stringer-Reasor</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>hormone-receptor positive breast cancer</keyword>
  <keyword>Her2 negative breast cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>everolimus</keyword>
  <keyword>TRC105</keyword>
  <keyword>letrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

